Xencor Inc. ( (XNCR) ) has released its Q3 earnings. Here is a breakdown of the information Xencor Inc. presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Xencor, Inc. is a clinical-stage biopharmaceutical company that focuses on developing engineered antibody therapeutics for cancer and autoimmune diseases. In its latest earnings report, Xencor reported a net loss of $6.03 million for the third quarter of 2025, a significant improvement from the $47.44 million loss in the same period last year. The company saw an increase in revenue from collaborations, milestones, and royalties, totaling $21 million for the quarter, up from $17.8 million the previous year. Key financial metrics include a decrease in cash and cash equivalents to $28.3 million from $40.9 million at the end of 2024, and a reduction in total assets to $868.8 million from $951.9 million. Despite the net loss, Xencor’s strategic partnerships with companies like Alexion and Incyte have resulted in significant milestone payments and royalty revenues. Looking ahead, Xencor remains focused on advancing its clinical programs and leveraging its partnerships to drive future growth.